Columbia University Irving Medical Center/New York-Presbyterian Hospital
With approximately 20 years of experience in translational neuro-oncology research, I focus on improving the understanding of brain cancers and expanding available therapies through translational clinical trials. I have designed and led phase 1-3 prospective trials and retrospective studies. All of these research efforts incorporate molecular correlative analyses to refine treatment paradigms. In recognition of these and other achievements I received the Preuss Award in Neuro-Oncology from the American Academy of Neurology, the Boyer Clinical Research Award from Memorial Sloan Kettering Cancer Center (MSKCC), the Neurology Resident Teaching Award from MSKCC/Weill Cornell, and the Adult Clinical Research Abstract Award from the Society for Neuro-Oncology.
To reach this point, I earned BS and MS degrees in Molecular Biophysics & Biochemistry from Yale, earned my MD from Columbia, completed Neurology Residency at NewYork-Presbyterian (NYP)/Columbia, and Neuro-Oncology Fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) which encompassed clinical and clinical research training and bench science in glioma molecular biology. Following fellowship, I joined MSKCC faculty from 2013-2011 where I later served as Director of the Neuro-Oncology Fellowship Training Program.
In 2011, I returned to NYP/Columbia as Neuro-Oncology Division Chief in the Neurology Department, building the brain tumor program from the ground-up to its current structure encompassing 6 faculty, an accredited fellowship, and multiple other clinical and administrative team members. I also serve as Associate Director for Clinical Trials for the NCI-designated Herbert Irving Comprehensive Cancer Center, overseeing the Data & Safety Monitoring Committee, Protocol Review & Monitoring Committees. Finally, I am Medical Director for the Clinical Protocol Data Management Office which is a centralized unit of nearly 100 full-time employees supporting execution of pilot through phase 3 clinical trials as well as cancer prevention and control studies across the full spectrum of human tumors.